Abstract
Background

Diabetes
Mellitus (DM) is a heterogeneous, etiologic and pathogenic syndrome, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action or both. Hyperglycemia and other associated abnormalities are leading to serious acute and chronic complications, which are reducing and altering the patient's life. The increasing prevalence of the disease and its main complications, micro and macrovascular, represents one of the main public health problems worldwide.
Because approximately 70-80% of diabetic patients die from cardiovascular events, DM can be considered an equivalent of cardiovascular disease (CVD) [1] .
Extended epidemiological trials revealed that cardiovascular risk is two up to four times increased in DM individuals compared to nondiabetic ones, its incidence and prevalence being influenced by gender, diseases duration and association with other illnesses ( Using HbA1c as a diagnosis criterion provides a series of advantages namely the fact that it doesn't need a period of fasting before assessment and it is not influenced by other factors such as stress or infections of any kind.
An HbA1c value between 5.7 to 6.4% indicates individuals with increased risk of developing diabetes and CVD, this span being named by specialists as prediabetes [14] [15] [16] .
Aims
Based on these assumptions, the objectives of the present study consisted in assessing the degree of glycemic control in a group of patients with diabetes, and to establish the correlations between chronic complications of diabetes and glycemic control assessed by HbA1c levels.
Material and method
We enrolled 2120 patients with type 2 DM, 1174 woman (55.4%) and 946 men (44.6%), with a mean age of 58.3±12.3 years (range 41 to 76 years), from Timisoara.
We investigated a series of clinical and biological parameters: age, gender, place of origin, duration of DM, therapy, body mass index (BMI), blood pressure (BP), HbA1c, total cholesterol (TC), serum triglycerides (TG), HDLc and LDLc (computed using Friedwald's formula).
We also investigated the presence of chronic complications of diabetes for the enrolled patients: microvascular (diabetic retinopathy -DR and diabetic nephropathy -DN), macrovascular (stroke, ischemic heart disease -IHD and peripheral artery disease -PAD) and neuropathic (distal sensory diabetic neuropathy -DSDN). Diagnostic of DR was based on fundoscopic examination and of DN on urine albumin/creatinine ratio.
Using SPSS, we calculated Spearman correlation coefficient, also named "the rank correlation coefficient", used to compare variables measured on ordinal scale or range.
Results
Main characteristics of the patients enrolled are shown in Table 1 . As shown in Table 1 , the mean HbA1c in the studied group was 8%±1.6%. We observed that only 556 patients (26.2%) from the entire lot belonged to the targeted group (HbA1c ≤7%, Figure 1 ).
In the study group 184 patients (8.7%) were treated only with diet, 1052 (49.6%) were on oral antidiabetic drugs and 884 (41.7%) were on insulin therapy with or without oral drugs.
Chronic DM complications have been investigated both in general and in relation to HbA1c value. In 34.2% of the cases microvascular complications (DR and DN) were found; in 52.7% macrovascular complications were found (stroke, IHD, PAD), Analyzing different intervals of HbA1c, adjusted regarding age, diabetes duration and BMI, we observed the lowest percentage of chronic complications of DM in the group with HbA1c values lower than 6%. We also found that their number increases with HbA1c, with a statistically significant raise in patients with HbA1c between 7 and 7.9% compared to those with values between 6 and 6.9% (p<0.0001) ( Table 2 ).
In the group of patients treated with insulin, 321 (36.3%) followed conventional treatment (regimens with 2 or 3 shots), and 563 (63.7%) were under intensive treatment (4 or 5 shots). HbA1c was significantly higher in patients under conventional treatment compared to those under intensive treatment: 9.1±1.7 % versus 8.2±1.2 % (p<0.0001). By comparing the occurrence of chronic complications in patients under conventional treatment versus those with intensive therapy, we found that the percentage is significantly higher in the first group (p<0.0001, Figure 3) . We found positive correlations between all investigated chronic complications (after adjusting regarding age, BMI and diabetes duration) of DM and the levels of HbA1c. Among them, the strongest correlations were between DR and HbA1c (r=0.64, p<0.001) and between DN and HbA1c (r=0.61, p<0.001). A moderate correlation was observed between DSDN and HbA1c (r=0.46, p<0.001 ES).
Discussions
Measuring the HbA1c value is commonly used in DM patients as a marker of glycemic control and also as a marker for changing the treatment or even for initiating insulin therapy when needed [17, 18] .
In 1993, DCCT proved that intensive insulin therapy reduced with 73% the risk of progression of DR compared to conventional treatment. In our study the prevalence of retinopathy was merely twofold higher in patients treated conventionally compared to those on intensive treatment: 54% versus 34% [4, 19, 20] .
These observations led to the recommendations of international societies to reduce HbA1c target from 7% to 6.5% in order to prevent chronic microvascular complications. An article by Mazzone M et al. proved that cardiovascular events are reduced in direct proportion with the improvement of the glycemic control: "A lower than 7% HbA1c is reasonable and safe", concluded Mazzone [21] .
A meta-analysis performed by a group from University of Cambridge, UK, suggests that a better glycemic control reduces the risk of myocardial infarct and cardiovascular disease, with no other influence regarding other causes of mortality.
The Action in Diabetes and Vascular Disease (ADVANCE) study, revealed the reduction of albuminuria progression with the improvement of the glycemic control, while Action to Control Cardiovascular Risk in Diabetes (ACCORD) was halted before planned date, due to increasing in mortality risk, in diabetic patients with very low HbA1c values [22] .
Like other important trials, UKPDS proved that improving glycemic control is reducing not only the main microvascular complications of DM but also the incidence of MI or other causes of mortality [23, 24, 25] .
It is known that a patient with DM dies mainly because cardiovascular events, and approximately 10 years earlier than nondiabetics.
Ray et al. enrolled 33.040 patients and compared the effects of standard treatment to the intensive one on the cardiovascular events and mortality in DM patients. Average HbA1c was 0.9% lower and the number of cardiovascular events was with 15% and MI with 17% lower in intensive treated patients [10] .
The Atherosclerosis Risk in Communities (ARIC) study revealed that HbA1c is a significant predictor for cardiovascular diseases (stroke, IHD or even death), even in patients having a normal value of HbA1c. In ARIC study, which included non-diabetic patients, HbA1c gained a higher level of trust for assessing long term cardiovascular diseases than fasting plasma glucose, especially in levels higher than 6%. HbA1c is therefore not only a key indicator of glycemic control for patients with diabetes, but also an important marker for cardiovascular disease (CVD). Taking these into accout, HbA1c was included as a diagnosis criterion in DM patients; therefore, patients with HbA1c values higher than 6.5% are classified as having DM, and those with values between 5.7% and 6.4% are considered having prediabetes.
A study conducted in Norfolk, which enrolled 4662 men and 5570 women aged between 45 and 79 years and analyzed the relationship between HbA1c, CVD and overall mortality, proved that individuals with HbA1c lower than 5% had the lowest incidence of cardiovascular events and global mortality. An increasing with 1% of HbA1c was associated with an increased relative risk of overall mortality with 1.24 in men and with 1.28 in women. This relative risk increase was independent of age, BMI, systolic blood pressure values, TC, smoking or history of CVD, but in our study we haven't found any significant correlation between HbA1c and macrovascular complications [26, 27] .
Similar to other trials, in our patients, the percentage of chronic microvascular complications of diabetes is increasing together with HbA1c, being significantly higher (about three times) in patients with values above 7%.
